Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy

Biochemical recurrence (BCR) is a common clinical event after radical prostatectomy (RP). Accurate risk stratification and timely individualized treatment are still major problems in clinical practice and research. Current clinical guidelines and key original studies describe several main components of BCR management after RP, including how BCR is defined, which factors affect prognosis, how imaging is used for evaluation, and which treatment options are available. These components help guide clinical decisions at different stages of care. Recent work has focused on the use of artificial intelligence (AI). Multimodal AI models that integrate clinical features, MRI-based radiomics, and whole-slide image pathology features demonstrate superior performance compared with single-modal approaches in predicting BCR after RP.